SCHEMBL2114929

SCHEMBL2114929

OC1CCCOc2ccc(Br)cc21

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADRA2A P08913 2/20 0.45
LMNA P02545 1/20 0.43
MAPT P10636 1/20 0.43
HTT P42858 1/20 0.43
BLM P54132 1/20 0.43
MAP3K14 Q99558 1/20 0.41
MEN1 O00255 1/20 0.38
NPC1 O15118 1/20 0.38
GAA P10253 1/20 0.38
RAB9A P51151 1/20 0.38
KMT2A Q03164 1/20 0.38
HTR1A P08908 2/20 0.37
CYP2D6 P10635 2/20 0.37
SLC6A4 P31645 2/20 0.37
DRD2 P14416 1/20 0.35
DRD3 P35462 1/20 0.35
HCRTR2 O43614 1/20 0.34
AHR P35869 1/20 0.34
PIK3CG P48736 1/20 0.34
MAOB P27338 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1271967 0.90 MAP3K14 (0.51) ADRA2ALMNAMAPTHTTBLM
SCHEMBL8350459 0.81 MAP3K14 (0.42) MAPTMAP3K14GAACYP2D6DRD2
SCHEMBL31603070 0.79 DRD2 (0.43) ADRA2ALMNAMAPTHTTBLM
SCHEMBL31603066 0.79 DRD2 (0.43) ADRA2ALMNAMAPTHTTBLM
SCHEMBL31136565 0.79 DRD2 (0.43) ADRA2ALMNAMAPTHTTBLM
SCHEMBL2114513 0.78 ADRA2A (0.46) ADRA2ALMNAMAPTHTTBLM
SCHEMBL9585693 0.76 DRD2 (0.40) LMNAMAP3K14CYP2D6DRD2DRD3
SCHEMBL9586005 0.76 ALDH1A1 (0.44) LMNAMAPTMAP3K14MEN1NPC1
SCHEMBL20449183 0.76 MAP3K14 (0.65) ADRA2ALMNAMAPTHTTBLM
SCHEMBL12501454 0.76 MAP3K14 (0.65) ADRA2ALMNAMAPTHTTBLM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8227468-B2 Cathepsin S inhibitor compounds ELI LILLY AND COMPANY (US) 2012-07-24 US disclosed
US-8227468-B2 Cathepsin S inhibitor compounds ELI LILLY AND COMPANY (US) 2012-07-24 US disclosed
US-8227468-B2 Cathepsin S inhibitor compounds ELI LILLY AND COMPANY (US) 2012-07-24 US disclosed
WO-2012054315-A1 CATHEPSIN S INHIBITOR COMPOUNDS ELI LILLY AND COMPANY (US) 2012-04-26 WO disclosed
US-20120095020-A1 Cathepsin S Inhibitor Compounds ELI LILLY AND COMPANY (US) 2012-04-19 US disclosed
US-20120095020-A1 Cathepsin S Inhibitor Compounds ELI LILLY AND COMPANY (US) 2012-04-19 US disclosed
US-20120095020-A1 Cathepsin S Inhibitor Compounds ELI LILLY AND COMPANY (US) 2012-04-19 US disclosed
US-5194442-A 2,3,4,5-tetrahydro-1-benzoxepins, the use thereof and pharmaceutical products based on these compounds HOECHST AKTIENGESELLSCHAFT (DE) 1993-03-16 US disclosed
EP-0360131-A1 2,3,4,5-Tetrahydro-1-benzoxepines, method for their preparation, their use and pharmaceutical compositions based on these compounds HOECHST AKTIENGESELLSCHAFT (DE) 1990-03-28 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120095020-A1 Cathepsin S Inhibitor Compounds CTSS, CTSZ, CTSV ADRA2A 1955/4885LMNA 718/4885MAPT 940/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.